Newcells Biotech Limited

Newcells Biotech Ltd, based in Newcastle Upon Tyne, UK, is a small, holding company with an active status. Established ten years ago in 2015, the company employs 42 people and holds assets totaling £4,208,562. While it has a registered address, it’s likely a virtual one, as fifty-one companies share the same location. Seven directors oversee operations, and three owners hold stakes in the business. Newcells Biotech regularly imports miscellaneous chemical products (for 31 months) and exports pharmaceutical products (for 13 months).

The company’s website reveals a focus on building functional in vitro models to improve clinical translation. It’s not an e-commerce business; instead, it offers services and products related to tissue modeling for drug discovery. They specialize in creating models of human tissues—specifically retina, kidney, and lung—to help researchers test drug safety and efficacy. They provide services like disease modeling, drug handling, and transporter studies, and even offer products like retinal organoids and kidney nephron models. The company’s website also highlights its expertise in imaging toxicology, gene therapy, and species comparison.

Financially, Newcells Biotech shows a mixed picture. Cash reserves decreased by 4.1% to £2.1 million, while net assets increased by 82% to £13 million. Bank borrowings decreased by 75%, a positive sign. Creditors increased by 21%, and trade debtors increased by 40%, which could indicate increased sales but also potential challenges in collecting payments. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) helps it remain agile. The company’s financial report was audited by Ryecroft Glenton. The increase in equity is a good sign, but the rise in debtors needs to be monitored.

Registered in England/Wales under the registration number 09389592, with a registered address at NE1 4BF, United Kingdom, Newcastle Upon Tyne, Tyne And Wear, Time Central, 32 Gallowgate.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.